Arterial hypertension (HT) has been reported in all studies involving bevacizumab, an
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …

Bevacizumab, a recombinant humanized monoclonal antibody targeting the vascular
endothelial growth factor (VEGF), has been approved in the US as first-and second-line …

Any of a number of therapeutic agents or chemical substances can induce transient or more
long-lasting forms of hypertension. Drugs that cause hypertension do so by either …

Background. Hypertension is a common toxicity of bevacizumab, but the frequency of
assessment of blood pressure and standardized grading remain to be defined. This study …

Background. Hypertension is associated with antivascular endothelial growth factor
treatment, but the clinical implications of hypertension are uncertain. To assess the …

Bevacizumab is a vascular endothelial growth factor-A-specific angiogenesis inhibitor
indicated as an adjunct to chemotherapy for the treatment of several types of cancer …

Purpose Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial
growth factor. The aim of this study was to gain a better understanding of the overall …

Background Hypertension is associated with the use of bevacizumab, an angiogenesis
inhibitor widely used in cancer therapy. Currently, the risk of severe hypertension associated …

Background: Hypertension (HT) is a common complication of anti-angiogenic therapy. Its
incidence, treatment and complications are undefined. Patients and Methods: Retrospective …

Purpose Bevacizumab is a monoclonal antibody that targets vascular endothelial growth
factor (VEGF) with demonstrated efficacy in combination with carboplatin and paclitaxel …